Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

Inclusion Criteria: * Received liver transplant for treatment of hATTR amyloidosis ≥12 months before study start * Has increase in polyneuropathy disability (PND) score after liver transplant * Has received stable immunosuppressive regimen with ≤10 mg/day of prednisone for at least 3 months before study start * Has Karnofsky Performance Status (KPS) of ≥70% * Has vitamin A level greater than or equal to lower limit of normal Exclusion Criteria: * Has previously received inotersen or patisiran * Has clinically significant liver function test abnormalities * Has known portal hypertension with ascites * Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73 m\^2 * Has known leptomeningeal amyloidosis * Has infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV) * Has New York Heart Association heart failure classification of \>2 * Is wheelchair bound or bedridden * Has received organ transplants other than liver transplant * Will be using another tetramer stabilizer during the study